皮肤鳞状细胞癌患者外周血PD-L1和PD-1表达与肿瘤免疫逃逸相关

doi:10.3969/j.issn.1001-8131.2023.01.002

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (818 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To clarify the expression of PD-L1 in Cutaneous Squamous Cell Carcinoma（cSCC）,and discuss their possible roles in tumor immune escape.Methods First,we used immunohistochemistry method to examined the expression of PD-L1 molecule in age-matched normal subject samples,precancerous lesion samples and clinical skin cSCC tissue samples.And immunofluorescence was applied to detect the expression of PD-L1 in primary epithelial cells and skin squamous cell line A431.In addition,we also detected the expression of PD-L1 in the peripheral blood CD14 positive cells and PD -1 in peripheral T cells of cSCC patients by flow cytometry method,then analyzed the differences in PD-L1 expression levels in different populations.Results Immunohistochemical results showed a significant upregulation of PD-L1 in actinic keratinized tissues and squamous cell carcinoma tissues and a significant down-regulation of PD-L1 in normal skin tissues.Resultsof immunofluorescence showed a strongly difference of PD-L1 between primary epithelial cells and skin squamous cell.Furthermore,the increase of PD-L1 was no strongly associated with gender,age,and tumor risk factors.In addition（P>0.05）,the results also proved a significant high expression of co-inhibitory molecules such as PD-L1 in peripheral blood CD 14 positive cells and PD-L1 ligands PD-1 in peripheral T cells of cSCC.Conclusion Our results suggest that PD-L1 plays an important role in the occurrence of cSCC and the immune escape of tumors,and it provides the possibility for PD-L1 molecules to be used as a potential target for early diagnosis and immunotherapy of cSCC.

Key words： Cutaneous Squamous Cell Carcinoma PD-L1 PD -1 Immune escape Immunotherapy

Received: 19 November 2021

PACS:

R751

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yang Xueqi
	Li Dan
	Min Wei

Cite this article:

Yang Xueqi,Li Dan,Min Wei. Peripheral Blood Expression of PD-L1 and PD-1 Associated With Tumor Immune Escape in Cutaneous Squamous Cell Carcinoma Patient[J]. journal1, 2023, 43(1): 5-8.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2023.01.002 OR http://www.hrbyybjb.org.cn/EN/Y2023/V43/I1/5

[1] Giovanna T.Analisi epidemiologica e caratterizzazione morfologica di pazienti affetti da tumore della cute non melanoma da registro nazionale[J].AIRTUM,2018,122(2):3-6
[2] Que SKT,Zwald FO,Schmults CD.Cutaneous squamous cell carcinoma:Incidence,risk factors,diagnosis,and staging[J].J Am Acad Dermatol,2018,78(2):237-247.
[3] Migden MR,Rischin D,Schmults CD,et al.PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma[J].N Engl J Med,2018,379(4):341-351.
[4] Soura E,Gagari E,Stratigos A.Advanced cutaneous squamous cell carcinoma:how is it defined and what new therapeutic approaches are available[J].CurrOpin Oncol,2019,31(5):461-468.
[5] Curiel T.Blockade of PD-L1 improves myeloid dendritic cell-mediated antitumor immunity[J].Nat Med,2003,9(3):562-567.
[6] Raez LE,Cassileth PA,Schlesselman JJ,et al.Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2004,22(14):2800-2807.
[7] Taube JM,Anders RA,Young GD,et al.Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J].Sci Transl Med,2012,4(127):12737.
[8] Benson DM Jr,Bakan CE,Mishra A,et al.The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect:a therapeutic target for CT-011,a novel monoclonal anti-PD-1 antibody[J].Blood,2010,116(13):2286-2294.
[9] Yoshinaga SK,Whoriskey JS,Khare SD,et al.T-cell co-stimulation through B7RP-1 and ICOS[J].Nature,1999,402(6763):827-832.
[10] Latchman Y,Wood CR,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nature Immunology,2001,2(3):261.
[11] Sica GL,Choi IH,Zhu G,et al.B7-H4,a molecule of the B7 family,negatively regulates T cell immunity[J].Immunity,2003,18(6):849-861.
[12] Nakanishi J,Wada Y,Matsumoto K,et al.Overexpression of B7-H1(PD-L1)significantly associates with tumor grade and postoperative prognosis in human urothelial cancers[J].Cancer Immunol Immunother,2007,56(8):1173-1182.
[13] Zhang G,Hou J,Shi J,et al.Soluble CD276(B7-H3)is released from monocytes,dendritic cells and activated T cells and is detectable in normal human serum[J].Immunology,2008,123(4):538-546.
[14] Gadiot J.Overall survival and PD-L1 expression in metastasized malignant melanoma[J].Cancer,2011,117(3):2192-2201.